Skip to the beginning of the images gallery

Opicapone - 98%, high purity , Catechol O-methyltransferase inhibitor, CAS No.923287-50-7, Catechol O-methyltransferase inhibitor

≥98%

CAS#: 923287-50-7
Formula: C₁₅H₁₀Cl₂N₄O₆
Molecular Weight: 413.17
PubChem CID: 135565903

Item Number

O356703

Grouped product items
SKU	Size	Availability	Price
O356703-1mg	1mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$49.90
O356703-5mg	5mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$134.90
O356703-10mg	10mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$227.90
O356703-25mg	25mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$425.90
O356703-50mg	50mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$637.90
O356703-100mg	100mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$891.90

View related series

Catechol-O-methyltransferase Inhibitor COMT Metabolic Enzyme/Protease Neuronal Signaling

Synonyms	5-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-1,2,4-oxadiazol-5-yl]-3-nitrobenzene-1,2-diol \| compound 37d [PMID: 20334432] \| SCHEMBL539065 \| ongentys \| 5-(3-(2,5-DICHLORO-4,6-DIMETHYL-1-OXY-PYRIDIN-3-YL)-(1,2,4)OXADIAZOL-5-YL)-3-NITROBENZENE
Specifications & Purity	Moligand™, ≥98%
Storage Temp	Store at 2-8°C
Shipped In	Wet ice
Grade	Moligand™
Action Type	INHIBITOR
Mechanism of action	Catechol O-methyltransferase inhibitor

IUPAC Name	5-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-1,2,4-oxadiazol-5-yl]-3-nitrobenzene-1,2-diol
INCHI	InChI=1S/C15H10Cl2N4O6/c1-5-10(13(17)20(24)6(2)11(5)16)14-18-15(27-19-14)7-3-8(21(25)26)12(23)9(22)4-7/h3-4,22-23H,1-2H3
InChi Key	ASOADIZOVZTJSR-UHFFFAOYSA-N
Canonical SMILES	CC1=C(C(=[N+](C(=C1Cl)C)[O-])Cl)C2=NOC(=N2)C3=CC(=C(C(=C3)O)O)[N+](=O)[O-]
Isomeric SMILES	CC1=C(C(=[N+](C(=C1Cl)C)[O-])Cl)C2=NOC(=N2)C3=CC(=C(C(=C3)O)O)[N+](=O)[O-]
PubChem CID	135565903
Molecular Weight	413.17

PubChem CID	135565903
CAS Registry No.	923287-50-7
Reactome Reaction	R-HSA-9679775
Reactome Drug	R-ALL-9679750

Lot Number	Certificate Type	Date	Item
E2430268	Certificate of Analysis	Feb 20, 2024	O356703
E2430269	Certificate of Analysis	Feb 20, 2024	O356703
E2430289	Certificate of Analysis	Feb 20, 2024	O356703
E2430290	Certificate of Analysis	Feb 20, 2024	O356703
E2430291	Certificate of Analysis	Feb 20, 2024	O356703
E2430302	Certificate of Analysis	Feb 20, 2024	O356703

Pictogram(s)	GHS07
Signal	Warning
Hazard Statements	H228:Flammable solid
Precautionary Statements	P280:Wear protective gloves/protective clothing/eye protection/face protection. P370+P378:In case of fire: Use ... to extinguish. P210:Keep away from heat, hot surface, sparks, open flames and other ignition sources. - No smoking. P240:Ground/bond container and receiving equipment. P241:Use explosion-proof [electrical/ventilating/lighting/.../] equipment.

Opicapone - 98%, high purity , Catechol O-methyltransferase inhibitor, CAS No.923287-50-7, Catechol O-methyltransferase inhibitor

Basic Description

Product Properties

Associated Targets(Human)

Associated Targets(non-human)

Mechanisms of Action

Names and Identifiers

Database links

Certificates

Certificate of Analysis(COA)

Safety and Hazards(GHS)

Related Documents

References

Solution Calculators

Molarity Calculator

Dilution Calculator

Reconstitution Calculator

1. Kiss LE, Ferreira HS, Torrão L, Bonifácio MJ, Palma PN, Soares-da-Silva P, Learmonth DA. (2010) Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.. J Med Chem, 53 (8): (3396-411). [PMID:20334432] [10.1021/op500134e]
2. Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P, Bi-Park 1 investigators. (2016) Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.. Lancet Neurol, 15 (2): (154-165). [PMID:26725544] [10.1021/op500134e]